CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma

iScience 2026 Open access

Read full text
Authors: Yilong Cao, Chao Xu, Yuepeng Liu, Bei Shi, Xiaoling Li, Jiehan Li, Bowei Zhang, Zeyuan Zhang, Shengtao Dai, Qingyun Sun, Junfei Gu
DOI: 10.1016/j.isci.2026.114840
Cited by: 1
References: 38

Abstract

studies demonstrated that the combined therapeutic intervention of CCT3 knockdown and the XPO1 inhibitor Selinexor significantly suppressed tumor growth in ccRCC xenograft models, validating the therapeutic potential of targeting the CCT3-XPO1 axis. In summary, our findings unveil a novel CCT3-XPO1-RB1 axis that orchestrates ccRCC progression by impairing cellular senescence, offering a promising therapeutic avenue for ccRCC treatment.

Fields of Study & Subjects

Connective Tissue Growth Factor Research Renal and related cancers Genetic and Kidney Cyst Diseases

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
3
Pages
114840–114840
Publication date
29 January 2026
Language
EN